ICCC - ImmuCell Corp Stock Price, Fair Value and News

4.89USD+0.09 (+1.88%)Delayed as of 17 May 2024, 01:57 pm ET

Market Summary

USD4.89+0.09

Delayedas of 17 May 2024, 01:57 pm

1.88%

ICCC Stock Price

View Fullscreen

ICCC RSI Chart

ICCC Valuation

Market Cap

37.5M

Price/Earnings (Trailing)

-9.62

Price/Sales (Trailing)

1.76

EV/EBITDA

-62.26

Price/Free Cashflow

-13.52

ICCC Price/Sales (Trailing)

ICCC Profitability

EBT Margin

-18.29%

Return on Equity

-15.82%

Return on Assets

-9.05%

Free Cashflow Yield

-7.4%

ICCC Fundamentals

ICCC Revenue

Revenue (TTM)

21.3M

Rev. Growth (Yr)

110.58%

Rev. Growth (Qtr)

42.42%

ICCC Earnings

Earnings (TTM)

-3.9M

Earnings Growth (Yr)

81.09%

Earnings Growth (Qtr)

61.58%

Breaking Down ICCC Revenue

52 Week Range

4.416.05

(Low)(High)

Last 7 days

-9.3%

Last 30 days

-4.9%

Last 90 days

-6.8%

Trailing 12 Months

-6.6%

How does ICCC drawdown profile look like?

ICCC Financial Health

Current Ratio

2.71

Debt/Equity

0.41

Debt/Cashflow

-0.15

ICCC Investor Care

Shares Dilution (1Y)

0.84%

Diluted EPS (TTM)

-0.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	21.3M	0	0	0
2023	16.0M	15.7M	16.3M	17.5M
2022	21.1M	20.5M	20.1M	18.6M
2021	14.5M	16.1M	17.5M	19.2M
2020	14.2M	14.5M	15.2M	15.3M
2019	12.5M	12.2M	13.0M	13.7M
2018	9.8M	11.0M	11.2M	11.0M
2017	10.1M	9.5M	9.5M	10.4M
2016	10.1M	10.5M	10.0M	9.5M
2015	8.6M	9.0M	9.7M	10.2M
2014	6.2M	6.4M	7.0M	7.6M
2013	5.5M	5.7M	5.9M	6.0M
2012	5.3M	5.2M	5.3M	5.4M
2011	4.6M	4.8M	4.9M	5.1M
2010	0	4.5M	4.4M	4.4M
2009	0	0	0	4.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ImmuCell Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 06, 2023	tomsche david scott	back to issuer	14,737	4.7541	3,100	-
Mar 14, 2023	tomsche david scott	back to issuer	10,879	5.49451	1,980	-
Mar 13, 2023	tomsche david scott	back to issuer	11,114	5.29281	2,100	-
Sep 12, 2022	tomsche david scott	back to issuer	6,217	7.76217	801	-
Sep 09, 2022	tomsche david scott	back to issuer	5,432	7.76017	700	-
Sep 08, 2022	tomsche david scott	back to issuer	6,970	7.69403	906	-
Jun 14, 2022	tomsche david scott	back to issuer	5,322	8.18846	650	-
Jun 13, 2022	tomsche david scott	back to issuer	11,559	7.78393	1,485	-
Jun 13, 2022	cunningham david	bought	8,000	8.00	1,000	-
Jun 09, 2022	tomsche david scott	back to issuer	12,748	8.49921	1,500	-

Which funds bought or sold ICCC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	reduced	-23.48	-87,487	342,995	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-0.15	412	10,770	-%
May 15, 2024	Cresset Asset Management, LLC	unchanged	-	25,902	549,112	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-2.96	110	10,616	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	sold off	-100	-774	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-72.12	-1,000	-	-%
May 14, 2024	NORTHERN TRUST CORP	reduced	-8.12	-7,194	158,974	-%
May 14, 2024	Bleichroeder LP	unchanged	-	21,335	538,448	0.13%
May 13, 2024	UBS Group AG	added	196	15,950	23,585	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	13,313	282,105	-%

Are Funds Buying or Selling ICCC?

Are funds buying ICCC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ICCC

No. of Funds

Unveiling ImmuCell Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 16, 2021	pessin norman h	9.10%	703,636	SC 13D/A
Feb 04, 2021	wellington management group llp	0.00%	0	SC 13G/A
Feb 03, 2021	wellington trust co n a	0.00%	0	SC 13G/A
Feb 03, 2021	wellington trust company, national association multiple common trust funds trust, micro cap equity p	0.00%	0	SC 13G/A
Jan 29, 2020	wellington trust co n a	9.48%	683,334	SC 13G
Jan 28, 2020	wellington management group llp	9.48%	683,334	SC 13G

Recent SEC filings of ImmuCell Corp

View All Filings

Date Filed	Form Type	Document
May 14, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 10, 2024	424B2	Prospectus Filed
Apr 10, 2024	424B2	Prospectus Filed
Apr 09, 2024	8-K	Current Report
Apr 09, 2024	8-K	Current Report
Apr 09, 2024	EFFECT	EFFECT
Apr 05, 2024	UPLOAD	UPLOAD
Apr 05, 2024	CORRESP	CORRESP

Peers (Alternatives to ImmuCell Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

ImmuCell Corp News

Latest updates

ImmuCell Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	42.4%	7,258	5,096	5,397	3,533	3,447	3,911	4,796	3,861	6,000	5,444	5,150	4,542	4,107	3,743	3,723	2,966	4,910	3,632	2,970	2,710	4,411
Gross Profit	82.5%	2,295	1,258	1,267	1,044	301	992	1,846	1,707	3,103	2,561	2,419	2,074	1,602	1,621	1,722	1,283	2,236	1,838	1,451	1,249	2,201
Operating Expenses	14.8%	2,595	2,261	2,451	2,348	2,557	2,626	2,463	2,326	2,533	2,415	2,148	1,859	1,977	2,255	1,974	1,975	2,039	2,081	1,881	1,796	1,936
S&GA Expenses	19.3%	801	672	817	720	879	993	727	659	812	890	656	437	521	660	459	466	583	690	498	524	607
R&D Expenses	18.4%	1,263	1,066	1,118	1,100	1,110	1,049	1,270	1,139	1,036	1,090	1,047	1,000	1,031	1,170	1,123	1,087	974	972	985	820	910
EBITDA Margin	76.6%	-0.04*	-0.15*	-0.20*	-0.20*	-0.15*	0.02*	0.10*	0.14*	0.17*	0.14*	0.16*	0.14*	-	-	-	-	-	-	-	-	-
Interest Expenses	-3.4%	136	141	-	-	88.00	91.00	88.00	88.00	72.00	74.00	77.00	79.00	79.00	73.00	75.00	76.00	256	96.00	105	108	112
Income Taxes	-0.6%	1.00	1.00	229*	2.00	2.00	2.00	4.00	1.00	1.00	1.00	8.00	-	-	4.00	-	-	-14.63	-3.62	7.00	15.00	9.00
Earnings Before Taxes	61.7%	-436	-1,138	-939	-1,378	-2,313	-1,666	-651	-683	514	75.00	156	141	-441	193	-322	-765	-136	-314	-495	-611	154
EBT Margin	44.6%	-0.18*	-0.33*	-0.39*	-0.38*	-0.33*	-0.13*	-0.04*	0.00*	0.04*	0.00*	0.00*	-0.03*	-	-	-	-	-	-	-	-	-
Net Income	61.6%	-437	-1,139	-940	-1,379	-2,315	-1,667	-655	-684	513	74.00	148	141	-441	189	-322	-765	-122	-310	-502	-627	145
Net Income Margin	44.6%	-0.18*	-0.33*	-0.39*	-0.38*	-0.33*	-0.13*	-0.04*	0.00*	0.04*	0.00*	0.00*	-0.03*	-	-	-	-	-	-	-	-	-
Free Cashflow	143.3%	348	-804	-928	-1,389	-3,444	-2,788	-1,992	-569	-168	-116	-416	-148	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.7%	43.00	44.00	45.00	44.00	43.00	45.00	46.00	46.00	47.00	44.00	44.00	44.00	40.00	40.00	40.00	41.00	40.00	39.00	39.00	39.00	40.00
Current Assets	-1.1%	11.00	11.00	12.00	11.00	12.00	14.00	16.00	17.00	18.00	16.00	16.00	16.00	12.00	12.00	10.00	11.00	11.00	13.00	14.00	14.00	15.00
Cash Equivalents	-1.9%	1.00	1.00	2.00	1.00	3.00	6.00	9.00	11.00	12.00	10.00	10.00	11.00	7.00	7.00	5.00	8.00	8.00	6.00	2.00	1.00	11.00
Inventory	-8.5%	7.00	8.00	7.00	8.00	6.00	6.00	5.00	5.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	2.00	2.00
Net PPE	-2.2%	27.00	28.00	28.00	29.00	28.00	28.00	28.00	27.00	27.00	27.00	27.00	27.00	26.00	27.00	27.00	26.00	26.00	25.00	25.00	25.00	26.00
Goodwill	0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-2.1%	18.00	19.00	19.00	17.00	15.00	14.00	14.00	13.00	14.00	12.00	12.00	11.00	12.00	12.00	12.00	12.00	11.00	10.00	10.00	10.00	10.00
Current Liabilities	-0.3%	4.00	4.00	3.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Long Term Debt	-3.5%	10.00	11.00	11.00	-	-	9.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-1.4%	25.00	25.00	26.00	27.00	28.00	30.00	32.00	33.00	33.00	33.00	32.00	32.00	28.00	28.00	28.00	28.00	29.00	29.00	29.00	30.00	30.00
Retained Earnings	-3.6%	-12.44	-12.01	-10.87	-9.93	-8.55	-6.23	-4.56	-3.91	-3.23	-3.74	-3.81	-3.96	-4.10	-3.66	-3.85	-3.53	-2.76	-2.64	-2.33	-1.83	-1.20
Additional Paid-In Capital	0.2%	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00	31.00
Shares Outstanding	0%	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	8.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	31.00	-	-	-	64.00	-	-	-	64.00	-	-	-	30.00	-	-	-	41.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	157.9%	419	-723	-507	-681	-2,761	-1,297	-1,258	373	639	588	259	731	-623	156	-667	969	857	-46.62	-66.41	-330	677
Share Based Compensation	-19.4%	81.00	101	96.00	76.00	96.00	65.00	85.00	62.00	54.00	41.00	45.00	23.00	35.00	57.00	62.00	57.00	77.00	92.00	69.00	70.00	83.00
Cashflow From Investing	-308.3%	-70.36	34.00	-533	-708	-682	-1,490	-734	-943	-796	-703	-671	-879	657	756	-1,473	-2,566	713	4,203	1,340	-8,742	-203
Cashflow From Financing	-14.0%	-366	-321	1,576	-251	749	-248	-223	-204	1,790	-194	208	4,042	-176	717	-143	1,296	41.00	-217	-215	-214	7,589

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ICCC Income Statement

2024-03-31

Statements of Operations (Unaudited) - USD ($)	3 Months Ended
Statements of Operations (Unaudited) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Product sales	$ 7,257,577	$ 3,446,527
Costs of goods sold	4,962,218	3,145,752
Gross margin	2,295,359	300,775
Product development expenses	1,262,550	1,110,368
Sales and marketing expenses	800,923	879,427
Administrative expenses	531,938	567,019
Operating expenses	2,595,411	2,556,814
NET OPERATING LOSS	(300,052)	(2,256,039)
Other expenses, net	136,476	57,489
LOSS BEFORE INCOME TAXES	(436,528)	(2,313,528)
Income tax expense	1,340	1,525
NET LOSS	$ (437,868)	$ (2,315,053)
Basic weighted average common shares outstanding (in Shares)	7,750,864	7,746,864
Basic net loss per share (in Dollars per share)	$ (0.06)	$ (0.3)
Diluted weighted average common shares outstanding (in Shares)	7,750,864	7,746,864
Diluted net loss per share (in Dollars per share)	$ (0.06)	$ (0.3)

ICCC Balance Sheet

2024-03-31

Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash and cash equivalents	$ 960,347	$ 978,741
Trade accounts receivable	2,622,532	2,185,383
Inventory	7,149,563	7,811,841
Prepaid expenses and other current assets	615,203	493,885
Total current assets	11,347,645	11,469,850
Property, plant and equipment, net	26,982,105	27,575,683
Operating lease right-of-use asset	4,546,061	4,571,149
Goodwill	95,557	95,557
Intangible assets, net	33,432	38,208
Other assets	46,248	57,655
TOTAL ASSETS	43,051,048	43,808,102
CURRENT LIABILITIES:
Current portion of debt obligations	1,443,791	1,428,807
Current portion of operating lease liability	597,289	644,276
Accounts payable and accrued expenses	2,142,859	2,124,337
Total current liabilities	4,183,939	4,197,420
LONG-TERM LIABILITIES:
Debt obligations, net of current portion	10,169,217	10,540,496
Operating lease liability, net of current portion	4,061,573	4,077,109
Total long-term liabilities	14,230,790	14,617,605
TOTAL LIABILITIES	18,414,729	18,815,025
CONTINGENT LIABILITIES AND COMMITMENTS (See Note 11)
STOCKHOLDER’ EQUITY:
Common stock, $0.10 par value per share, 15,000,000 shares authorized, 7,814,165 shares issued and 7,750,864 shares outstanding as of both March 31, 2024 and December 31, 2023	781,417	781,417
Additional paid-in capital	36,438,349	36,357,239
Accumulated deficit	(12,444,965)	(12,007,097)
Treasury stock, at cost, 63,301 shares as of both March 31, 2024 and December 31, 2023	(138,482)	(138,482)
TOTAL STOCKHOLDERS’ EQUITY	24,636,319	24,993,077
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 43,051,048	$ 43,808,102

About ImmuCell Corp

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

CEO	Mr. Michael F. Brigham
WEBSITE	https://immucell.com
INDUSTRY	Biotechnology
EMPLOYEES	66

ImmuCell Corp Frequently Asked Questions

What is the ticker symbol for ImmuCell Corp? What does ICCC stand for in stocks?

ICCC is the stock ticker symbol of ImmuCell Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ImmuCell Corp (ICCC)?

As of Thu May 16 2024, market cap of ImmuCell Corp is 37.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICCC stock?

You can check ICCC's fair value in chart for subscribers.

What is the fair value of ICCC stock?

You can check ICCC's fair value in chart for subscribers. The fair value of ImmuCell Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ImmuCell Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ICCC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ImmuCell Corp a good stock to buy?

The fair value guage provides a quick view whether ICCC is over valued or under valued. Whether ImmuCell Corp is cheap or expensive depends on the assumptions which impact ImmuCell Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICCC.

What is ImmuCell Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, ICCC's PE ratio (Price to Earnings) is -9.62 and Price to Sales (PS) ratio is 1.76. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICCC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ImmuCell Corp's stock?

In the past 10 years, ImmuCell Corp has provided 0.019 (multiply by 100 for percentage) rate of return.